Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Blast phase myeloproliferative...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

Bibliographic Details
Main Authors: Maymona G. Abdelmagid, Aref Al-Kali, Kebede H. Begna, William J. Hogan, Mark R. Litzow, Farah Fleti, Abhishek A. Mangaonkar, Mrinal S. Patnaik, Michelle A. Elliott, Hassan Alkhateeb, Min Shi, Matthew T. Howard, Kaaren K. Reichard, Rhett P. Ketterling, Mithun Shah, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Format: Article
Language:English
Published: Ferrata Storti Foundation 2023-02-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/10989
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://haematologica.org/article/view/10989

Similar Items

  • Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
    by: Naseema Gangat, et al.
    Published: (2023-01-01)
  • Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
    by: Ayalew Tefferi, et al.
    Published: (2024-03-01)
  • Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
    by: Abhishek A. Mangaonkar, et al.
    Published: (2022-02-01)
  • CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
    by: Rimal Ilyas, et al.
    Published: (2023-02-01)
  • Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
    by: Terra L. Lasho, et al.
    Published: (2018-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs